Please login to the form below
phase 3 trial
This page shows the latest phase 3 trial news and features for those working in and with pharma, biotech and healthcare.
Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
In June, the companies shared positive results from a phase 2/3 trial of two Omicron-adapted vaccine candidates, demonstrating the safety, tolerability and immunogenicity of the two candidates, and plan ... older. The FDA granted Pfizer and BioNTech
Latest news
-
Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
Pfizer and BioNTech have shared positive results from a phase 2/3 trial of two Omicron-adapted COVID-19 vaccine candidates. ... The phase 2/3 trial involved 1, 234 participants aged 56 and older.
-
Bristol Myers Squibb announces positive trial results for treatment of MS
In the two phase 3 trials, Zeposia treatment showed improved or preserved cognitive function in the majority of patients. ... Zeposia was well tolerated with more than 80% of people who started the phase 3 SUNBEAM trial remaining on continuous therapy
-
Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme
The programme was granted Fast Track designation by the US Food and Drug Administration (FDA) in July 2017, with Pfizer and Valneva expecting to initiate their phase 3 trial this year, ... disease.”. The anticipation for the phase 3 trial comes after
-
MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
MSD – known as Merck &Co in the US and Canada – and AstraZeneca have shared positive results from the PROpel phase 3 trial for the combination therapy of Lynparza (olaparib) plus abiraterone ... The results from the randomised phase 3 trial have been
-
FDA grants Pfizer/BioNTech’s COVID-19 vaccine emergency use authorisation for infants
The authorisation was based on data from a phase 2/3 randomised, controlled trial involving 4, 526 children aged six months to four years.
More from news
Approximately 3 fully matching, plus 593 partially matching documents found.
Latest Intelligence
-
Health technology assessments: understanding the global landscape and considerations for drug development
Clinical trial design. When feasible, phase 3 trials should be optimised to meet payer expectations. ... This step allows sponsors the opportunity to make changes to their clinical trial protocol, ensuring trials generate payer-relevant data.
-
Exploring the potential of eosinophils
Results from a comprehensive phase 3 clinical trial programme so far indicate that it could. ... GSK is now conducting a further phase 3 study in this area and while Howarth notes they have no results as yet, and it will be a while before they do,
-
Gut instincts lead Takeda to GI pipeline success
It is targeted for market approval in 2022. The promise continues with a phase 3 trial deploying Entyvio as a support for stem cell transplantation cancer treatments that are vulnerable to ... The product is entering a phase 2 study. “Coeliac disease
-
COVID-19: the race to find a vaccine
Roche, for example, is running a phase 3 trial to test whether Actemra improves outcomes by dampening hyperinflammation. ... A clinical trial of Regeneron’s drug is scheduled to start in June.
-
GSK forges ahead with its dynamic COPD and asthma portfolio
The promise includes a vaccine, which will report on phase 2 trials later this year, continuing work to identify biomarkers, and the start of a phase 3 trial of its therapy ... 3 trial having recently started.
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest appointments
-
New hires at Nanoform, Leo Pharma and Calliditas
During his time at Novo Nordisk, he led the strategic regulatory input for the orphan drug NovoEight from phase 1 through phase 3. ... With the phase 3 trial of Nefecon well underway, this is a pivotal time for the company.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Food Allergy – Is avoidance the only option?
Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. ... Efficacy and safety of oral immunotherapy in children aged 1–3
-
Clinical trials and the diversity principle
The following month, it happened again. Cambridge, Massachusetts-based Moderna said it had slowed enrolment in its phase 3 COVID-19 vaccine trial to ensure they were getting a representative population. ... With a dozen competitive vaccine trials in
-
Is the world ready for a COVID-19 vaccine?
3 clinical trial. ... Since this initial announcement, other good news in vaccine development has followed, with companies and collaborations, including Moderna and the AstraZeneca/University of Oxford team, publishing similarly positive trial results.
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
In its earlier phase 1 monotherapy trial, TAVO demonstrated a 46% response rate in untreated lesions in metastatic melanoma. ... Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally
-
Alzheimer’s disease: reviewing the immediate treatment horizon
Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease. ... Amyloid Treatment in AD Prevention Trial (Phase 3) respectively.
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Moderna to launch Innovation and Technology Center in the UK
- Biogen and Happify Health team up to create digital platform for MS patients
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
- VMLY&R wins two Grand Prix awards at Cannes Lions International Festival of Creativity 2022
- How digital health is changing the relationship between patients and health providers | OPEN Health
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Roche shares new positive Ocrevus data for MS patients
- Six UK universities receive grant for research into motor neurone disease
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
